| Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults (NCT07638800) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-07-28 |
| A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. (NCT07547995) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-06-29 |
| GenSci144 Tablets Phase I Clinical Trial (NCT07685210) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-06-22 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) (NCT07663838) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-06-15 |
| To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . (NCT07534176) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-05-20 |
| Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART) (NCT07553728) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-05-01 |
| Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD (NCT07423533) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-04-30 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants (NCT07476586) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-04-20 |
| GS1-144 in Participants With Hepatic Impairment and Healthy Female (NCT07491289) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-04-20 |
| A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants (NCT07537231) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-04-09 |
| GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors. (NCT07407504) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-04-01 |
| A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. (NCT07366866) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-03-16 |
| A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (NCT07450053) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-03-06 |
| A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (NCT07450001) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-03-06 |
| Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (NCT07356037) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-01-10 |
| A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults (NCT07473570) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2026-01-07 |
| GenSci143 in Participants With Advanced Solid Tumors (NCT07252414) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-20 |
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) (NCT07259564) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-19 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors (NCT07251166) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-10 |
| A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) (NCT07264595) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-01 |
| A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women (NCT07302035) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-01 |
| A Study of GensSci098 in Subjects With Graves' Disease (NCT07286656) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-11-21 |
| GenSci139 in Patients With Advanced Solid Tumors (NCT07230977) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-11-19 |
| A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics (NCT07260500) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-11-11 |
| Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (NCT07130617) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-09-29 |
| A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia (NCT07243379) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-09-25 |
| A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (NCT07124221) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-09-12 |
| Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China. (NCT07040930) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-08-01 |
| A Study on Bioequivalence of Cabergoline Tablets in Human Body (NCT07008417) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-06-30 |
| A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation (NCT06908434) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-06-10 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) (NCT07016802) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-06-09 |
| Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis (NCT06961188) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-06-01 |
| A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain (NCT06963177) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-05-26 |
| Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase (NCT06961201) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-05-01 |
| A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations (NCT06840691) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-05-01 |
| A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women (NCT06983925) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-04-30 |
| Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors (NCT06940102) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-03-12 |
| A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults. (NCT06827457) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-02-20 |
| A Bioequivalence Study of Two Different PEG-rhGH Preparations (NCT06797505) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-02-10 |
| Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue (NCT06830018) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-01-23 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors (NCT06772415) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-01-08 |
| Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. (NCT06772428) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-01-01 |
| Real-World Clinical Study for Malignant Tumor-Induced Cachexia (NCT07008248) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-10-15 |
| Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women. (NCT06726850) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-10-14 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease (NCT06569758) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-09-24 |
| To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection (NCT06561594) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-09-20 |
| Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. (NCT06449027) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-08-21 |
| Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome (NCT07691125) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-07-31 |
| A Bioequivalence Study of Two Different Dosage Form of Genakumab (NCT06451848) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-06-24 |
| A Bioavailability Study of Two Different PEG-rhGH Preparations. (NCT06385145) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-05-08 |
| A Bioequivalence Study of Two Different PEG-rhGH Preparations. (NCT06331026) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-04-09 |
| Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (NCT06321107) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-03-01 |
| A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers (NCT06204250) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-02-27 |
| A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population (NCT06385158) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-01-03 |
| A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency (NCT06024967) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-12-01 |
| To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. (NCT05925452) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-12-01 |
| A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency (NCT06007417) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-12-01 |
| A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations (NCT06135155) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-11-06 |
| A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations (NCT06135168) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-10-31 |
| A Study for the Treatment of Dry Eye in Postmenopausal Women (NCT06133166) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-09-20 |
| The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site (NCT06095206) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-09-19 |
| A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) (NCT05936281) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-07-20 |
| To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects. (NCT05921890) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-06-19 |
| To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (NCT06091436) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-03-24 |
| To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer. (NCT05673694) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-03-08 |
| Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults (NCT05894148) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-03-06 |
| Safety & Efffficacy of Genakumab in Patients With Frequent Flares (NCT05983445) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-01-11 |
| A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome (NCT06722079) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-11-08 |
| GS3-007a Oral Solution in Healthy Subjects (NCT05611281) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-09-22 |
| A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia (NCT05353192) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-08-20 |
| The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart. (NCT06984159) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-07-12 |
| Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors (NCT05441046) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-06-07 |
| Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma. (NCT05919381) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-05-30 |
| A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence (NCT05674045) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-01-06 |
| Clinical Study of Genakumab for Injection in Patients With Acute Gout (NCT05328531) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-05-22 |
| Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NCT05221385) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-12 |
| Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT05263271) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-01 |
| A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer (NCT04053205) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2019-11-05 |
| Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers (NCT04337437) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2019-04-22 |
| A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation (NCT03535415) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2018-06-25 |
| Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS (NCT03635580) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2018-06-11 |
| A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome (NCT03554031) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2018-04-14 |
| Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China (NCT03313219) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2017-10-11 |